Evidence map›Paper›PMID 35397545›Full record

ArticleBMC cancer2022

Invadopodia play a role in prostate cancer progression.

Valeria Manuelli, Fidelma Cahill, Harriet Wylie, Cheryl Gillett, Isabel Correa, Susanne Heck, Alex Rimmer, Anna Haire, Mieke Van Hemelrijck, Sarah Rudman and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Valeria ManuelliSchool of Cancer and Pharmaceutical Sciences, Kings College London, Rm.2.34A New Hunts House, London, SE1 1UL, UK.
Fidelma CahillDepartment of Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Harriet WylieDepartment of Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Cheryl GillettSchool of Cancer and Pharmaceutical Sciences, Kings College London, Rm.2.34A New Hunts House, London, SE1 1UL, UK.
Isabel CorreaNIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals, King's College London, London, UK.
Susanne HeckInstitute of Diabetes Research, Helmholtz Zentrum Munchen, Munich, Germany.
Alex RimmerSchool of Cancer and Pharmaceutical Sciences, Kings College London, Rm.2.34A New Hunts House, London, SE1 1UL, UK.
Anna HaireDepartment of Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Mieke Van HemelrijckSchool of Cancer and Pharmaceutical Sciences, Kings College London, Rm.2.34A New Hunts House, London, SE1 1UL, UK.
Sarah RudmanDepartment of Translational Oncology and Urology Research, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Claire M WellsSchool of Cancer and Pharmaceutical Sciences, Kings College London, Rm.2.34A New Hunts House, London, SE1 1UL, UK. claire.wells@kcl.ac.uk.
King's College London · GBGuy's and St Thomas' NHS Foundation Trust · GBInstitute of Diabetes Research

Funding

Cancer Research UK C604/A25135Medical Research Council MRC-DTPPancreatic Cancer Research Fund project 2017
6 · The paper itself

Abstract

backgroundInvadopodia, actin-rich structures that release metallo-proteases at the interface with extra-cellular matrix, in a punctate manner are thought to be important drivers of tumour invasion. Invadopodia formation has been observed in-vitro and in-vivo in numerous metastatic cell lines derived from multiple tumour types. However, prostate cancer cell lines have not been routinely reported to generate invadopodia and the few instances have always required external stimulation.

methodsIn this study, the invasive potential of primary prostate adenocarcinoma cell lines, which have never been fully characterised before, was investigated both in-vitro invadopodia assays and in-vivo zebrafish dissemination assay. Subsequently, circulating tumour cells from prostate cancer patients were isolated and tested in the invadopodia assay.

resultsRetention of E-cadherin and N-cadherin expression indicated a transitional state of EMT progression, consistent with the idea of partial EMT that has been frequently observed in aggressive prostate cancer. All cell lines tested were capable of spontaneous invadopodia formation and possess a significant degradative ability in-vitro under basal conditions. These cell lines were invasive in-vivo and produced visible metastasis in the zebrafish dissemination assay. Importantly we have proceeded to demonstrate that circulating tumour cells isolated from prostate cancer patients exhibit invadopodia-like structures and degrade matrix with visible puncta. This work supports a role for invadopodia activity as one of the mechanisms of dissemination employed by prostate cancer cells.

conclusionThe combination of studies presented here provide clear evidence that invadopodia activity can play a role in prostate cancer progression.

Indexed as

Neoplastic Cells, CirculatingPodosomesProstatic NeoplasmsAnimalsCell Line, TumorExtracellular MatrixHumansMaleNeoplasm InvasivenessProstateZebrafishCirculating tumour cellsInvadopodiaProstate cancer

Identifiers

PMID35397545
PMCPMC8994910
OpenAlexW4223441634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.